Select Page

Author: Kevin Schnurr

Alport Odyssey Zine

March 23, 2023 ASF is requesting U.S. patient submissions for the inaugural publication of Alport Odyssey, a zine exploring the Alport syndrome experience through the creative works of Alport patients. ​Alport Odyssey is a​​ space for patients to explore their lived experiences with​ ​Alport Syndrome by sharing artistic representations of stories, lessons, and reflections with […]

re: FDA Decision on Bardoxolone Methyl

                                                                                                                        February 25, 2022 On February 25th, the U.S. Food and Drug Administration (FDA) announced its decision not to approve a New Drug Application for the use of bardoxolone methyl as a treatment for Alport syndrome. Bardoxolone methyl was investigated for safety and efficacy in Alport patients through the CARDINAL Study, the first-ever clinical trial […]